The company has significantly improved its development of an novel therapy for amyloid heart disease, utilizing the investigational drug. Preliminary clinical results indicates potential outcomes for patients affected https://bridgebio015233.activablog.com/41078090/firm-advances-amyloidosis-treatment-using-attruby